iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.
Company profile
Ticker
ITRM
Exchange
Website
CEO
Corey N. Fishman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Iterum Therapeutics Ltd
SEC CIK
Corporate docs
Subsidiaries
Iterum Therapeutics International Limited • Iterum Therapeutics US Limited • Iterum Therapeutics US Holding Limited • Iterum Therapeutics Bermuda Limited ...
ITRM stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Apr 24
8-K
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
29 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Iterum Therapeutics Provides Business Update
6 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
30 Jan 24
8-K
Regulation FD Disclosure
30 Jan 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
DEFA14A
Additional proxy soliciting materials
14 Dec 23
DEF 14A
Definitive proxy
14 Dec 23
PRE 14A
Preliminary proxy
4 Dec 23
Transcripts
ITRM
Earnings call transcript
2023 Q4
28 Mar 24
ITRM
Earnings call transcript
2023 Q3
14 Nov 23
ITRM
Earnings call transcript
2023 Q2
11 Aug 23
ITRM
Earnings call transcript
2022 Q4
16 Mar 23
ITRM
Earnings call transcript
2022 Q3
10 Nov 22
ITRM
Earnings call transcript
2021 Q4
28 Mar 22
ITRM
Earnings call transcript
2021 Q3
12 Nov 21
ITRM
Earnings call transcript
2021 Q2
13 Aug 21
ITRM
Earnings call transcript
2021 Q1
14 May 21
ITRM
Earnings call transcript
2020 Q4
12 Mar 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.82 mm | 4.82 mm | 4.82 mm | 4.82 mm | 4.82 mm | 4.82 mm |
Cash burn (monthly) | 2.97 mm | 1.31 mm | 5.56 mm | 3.87 mm | 3.09 mm | 2.56 mm |
Cash used (since last report) | 19.88 mm | 8.75 mm | 37.20 mm | 25.88 mm | 20.65 mm | 17.14 mm |
Cash remaining | -15.07 mm | -3.94 mm | -32.38 mm | -21.06 mm | -15.84 mm | -12.32 mm |
Runway (months of cash) | -5.1 | -3.0 | -5.8 | -5.4 | -5.1 | -4.8 |
Institutional ownership, Q2 2023
67.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 1.48 bn |
Total shares | 11.15 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Leaf Venture Management III, L.L.C. | 3.91 mm | $3.87 mm |
Intracoastal Capital | 2.58 mm | $2.55 mm |
Canaan X | 1.73 mm | $1.71 mm |
Frazier Healthcare VII | 1.54 mm | $748.00 k |
Pivotal bioVenture Partners Fund I | 945.09 k | $935.00 k |
Apollon Wealth Management | 200.00 k | $214.00 mm |
New Leaf Venture Partners, L.L.C. | 97.08 k | $103.88 mm |
Sabby Management | 75.00 k | $1.13 bn |
Renaissance Technologies | 42.78 k | $46.00 k |
MS Morgan Stanley | 13.95 k | $14.93 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Dec 23 | Michael W. Dunne | Ordinary Shares | Buy | Acquire P | No | No | 1.4 | 25,000 | 35.00 k | 113,754 |
18 Dec 23 | Michael W. Dunne | Ordinary Shares | Buy | Acquire P | No | No | 1.8442 | 10,000 | 18.44 k | 88,754 |
1 Dec 23 | Puttagunta Sailaja | Ordinary Shares | Payment of exercise | Dispose F | No | No | 2.12 | 2,933 | 6.22 k | 10,369 |
1 Dec 23 | Puttagunta Sailaja | Ordinary Shares | Grant | Acquire A | No | No | 0 | 8,333 | 0.00 | 13,302 |
1 Dec 23 | Puttagunta Sailaja | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | No | 0 | 8,333 | 0.00 | 16,666 |
22 Nov 23 | Michael W. Dunne | Ordinary Shares | Buy | Acquire P | No | No | 2.0345 | 20,000 | 40.69 k | 78,754 |
20 Nov 23 | Fishman Corey N. | Ordinary Shares | Buy | Acquire P | No | No | 1.5863 | 10,000 | 15.86 k | 54,449 |
News
HC Wainwright & Co. Reiterates Buy on Iterum Therapeutics, Maintains $6 Price Target
1 Apr 24
Update: Iterum Therapeutics Q4 Adjusted EPS $(0.81) Beats $(0.94) Estimate
28 Mar 24
Iterum Therapeutics Q4 Adj EPS $(0.81) Beats $(0.93) Estimate
28 Mar 24
Iterum Therapeutics Q4 2023 GAAP EPS $(0.94), Inline, Cash Position $23.9M
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
Press releases
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
1 Apr 24
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
21 Mar 24
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
30 Jan 24